EGFR and non-small cell lung carcinoma: Three generations of EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs) have been approved for use in first‐line treatment for EGFR‐mutant NSCLC patients with BMs.4, 5, 6, 7, 8, 9